Curis Inc (CRIS) stock

CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30

$0.45−0.13 (-22.18%)

Close on Nov 13, 2026Market cap $930.08KP/E –Yield –

Curis EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Curis's EV/EBITDA was 85.2× on Jan 31, 2013.

Period	Period end	Value	Change (pts)
2013	Jan 31, 2013	85.2×	−8.0
2012	Dec 31, 2012	93.2×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CRIS.

Revenue growth-13.4% · median -38.4%

Operating margin-112.1% · median -3094.6%

Net margin-228.1% · median -2837.0%

Advertisement
300 × 250

See a number that looks wrong?